Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.

Kasikara C, Davra V, Calianese D, Geng K, Spires TE, Quigley M, Wichroski M, Sriram G, Suarez-Lopez L, Yaffe MB, Kotenko SV, De Lorenzo MS, Birge RB.

Cancer Res. 2019 May 15;79(10):2669-2683. doi: 10.1158/0008-5472.CAN-18-2614. Epub 2019 Mar 15.

PMID:
30877108
2.

[2.2.1]-Bicyclic sultams as potent androgen receptor antagonists.

Shan W, Balog A, Nation A, Zhu X, Chen J, Cvijic ME, Geng J, Rizzo CA, Spires T Jr, Attar RM, Obermeier M, Traeger S, Dai J, Zhang Y, Galella M, Trainor G, Vite GD, Gavai AV.

Bioorg Med Chem Lett. 2016 Dec 1;26(23):5707-5711. doi: 10.1016/j.bmcl.2016.10.059. Epub 2016 Oct 21.

PMID:
27836399
3.

Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer.

Huang A, Jayaraman L, Fura A, Vite GD, Trainor GL, Gottardis MM, Spires TE, Spires VM, Rizzo CA, Obermeier MT, Elzinga PA, Todderud G, Fan Y, Newitt JA, Beyer SM, Zhu Y, Warrack BM, Goodenough AK, Tebben AJ, Doweyko AM, Gold DL, Balog A.

ACS Med Chem Lett. 2015 Dec 2;7(1):40-5. doi: 10.1021/acsmedchemlett.5b00310. eCollection 2016 Jan 14.

4.

Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.

Balog A, Rampulla R, Martin GS, Krystek SR, Attar R, Dell-John J, DiMarco JD, Fairfax D, Gougoutas J, Holst CL, Nation A, Rizzo C, Rossiter LM, Schweizer L, Shan W, Spergel S, Spires T, Cornelius G, Gottardis M, Trainor G, Vite GD, Salvati ME.

ACS Med Chem Lett. 2015 Jun 19;6(8):908-12. doi: 10.1021/acsmedchemlett.5b00173. eCollection 2015 Aug 13.

5.

Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease.

Benn CL, Luthi-Carter R, Kuhn A, Sadri-Vakili G, Blankson KL, Dalai SC, Goldstein DR, Spires TL, Pritchard J, Olson JM, van Dellen A, Hannan AJ, Cha JH.

J Neuropathol Exp Neurol. 2010 Aug;69(8):817-27. doi: 10.1097/NEN.0b013e3181ea167f.

PMID:
20613636
6.

Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists.

Xiao HY, Balog A, Attar RM, Fairfax D, Fleming LB, Holst CL, Martin GS, Rossiter LM, Chen J, Cvjic ME, Dell-John J, Geng J, Gottardis MM, Han WC, Nation A, Obermeier M, Rizzo CA, Schweizer L, Spires T Jr, Shan W, Gavai A, Salvati ME, Vite G.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4491-5. doi: 10.1016/j.bmcl.2010.06.034. Epub 2010 Jun 10.

PMID:
20584610
7.

Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer.

Attar RM, Jure-Kunkel M, Balog A, Cvijic ME, Dell-John J, Rizzo CA, Schweizer L, Spires TE, Platero JS, Obermeier M, Shan W, Salvati ME, Foster WR, Dinchuk J, Chen SJ, Vite G, Kramer R, Gottardis MM.

Cancer Res. 2009 Aug 15;69(16):6522-30. doi: 10.1158/0008-5472.CAN-09-1111. Epub 2009 Aug 4.

8.

Neuropathology of Alzheimer's disease.

Gomez-Isla T, Spires T, De Calignon A, Hyman BT.

Handb Clin Neurol. 2008;89:233-43. doi: 10.1016/S0072-9752(07)01222-5. No abstract available.

PMID:
18631748
9.

Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease.

van Dellen A, Cordery PM, Spires TL, Blakemore C, Hannan AJ.

BMC Neurosci. 2008 Apr 1;9:34. doi: 10.1186/1471-2202-9-34.

10.

The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.

Schweizer L, Rizzo CA, Spires TE, Platero JS, Wu Q, Lin TA, Gottardis MM, Attar RM.

BMC Cell Biol. 2008 Jan 24;9:4. doi: 10.1186/1471-2121-9-4.

11.

Vigabatrin, a GABA transaminase inhibitor, reversibly eliminates tinnitus in an animal model.

Brozoski TJ, Spires TJ, Bauer CA.

J Assoc Res Otolaryngol. 2007 Mar;8(1):105-18. Epub 2007 Jan 13.

12.

Molecular mechanisms mediating pathological plasticity in Huntington's disease and Alzheimer's disease.

Spires TL, Hannan AJ.

J Neurochem. 2007 Feb;100(4):874-82. Epub 2007 Jan 8. Review.

13.

Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo.

Fulga TA, Elson-Schwab I, Khurana V, Steinhilb ML, Spires TL, Hyman BT, Feany MB.

Nat Cell Biol. 2007 Feb;9(2):139-48. Epub 2006 Dec 24.

PMID:
17187063
14.

Spine tingling polymorphisms--is apolipoprotein E involved in dendritic shape and plasticity?

Spires TL, Hyman BT.

Neurobiol Aging. 2007 May;28(5):687-8; discussion 704-6. Epub 2006 Oct 9. Review. No abstract available.

PMID:
17030473
15.

Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy.

Spires TL, Orne JD, SantaCruz K, Pitstick R, Carlson GA, Ashe KH, Hyman BT.

Am J Pathol. 2006 May;168(5):1598-607.

16.

Transgenic models of Alzheimer's disease: learning from animals.

Spires TL, Hyman BT.

NeuroRx. 2005 Jul;2(3):423-37. Review.

17.

Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.

Fink BE, Gavai AV, Tokarski JS, Goyal B, Misra R, Xiao HY, Kimball SD, Han WC, Norris D, Spires TE, You D, Gottardis MM, Lorenzi MV, Vite GD.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1532-6. Epub 2006 Jan 4.

PMID:
16386902
18.

Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy.

Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT.

J Neurosci. 2005 Aug 3;25(31):7278-87.

19.

Tau suppression in a neurodegenerative mouse model improves memory function.

Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH.

Science. 2005 Jul 15;309(5733):476-81.

20.

Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).

Spires TE, Fink BE, Kick EK, You D, Rizzo CA, Takenaka I, Lawrence RM, Ruan Z, Salvati ME, Vite GD, Weinmann R, Attar RM, Gottardis MM, Lorenzi MV.

Prostate. 2005 Oct 1;65(2):159-70.

PMID:
15924334
22.

Activity-dependent regulation of synapse and dendritic spine morphology in developing barrel cortex requires phospholipase C-beta1 signalling.

Spires TL, Molnár Z, Kind PC, Cordery PM, Upton AL, Blakemore C, Hannan AJ.

Cereb Cortex. 2005 Apr;15(4):385-93.

PMID:
15749982
23.

Neuronal structure is altered by amyloid plaques.

Spires TL, Hyman BT.

Rev Neurosci. 2004;15(4):267-78. Review.

PMID:
15526551
24.

Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice.

Spires TL, Grote HE, Garry S, Cordery PM, Van Dellen A, Blakemore C, Hannan AJ.

Eur J Neurosci. 2004 May;19(10):2799-807.

PMID:
15147313
25.

Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism.

Spires TL, Grote HE, Varshney NK, Cordery PM, van Dellen A, Blakemore C, Hannan AJ.

J Neurosci. 2004 Mar 3;24(9):2270-6.

26.

The synthesis of megatubes: new dimensions in carbon materials.

Mitchell DR, Brown RM Jr, Spires TL, Romanovicz DK, Lagow RJ.

Inorg Chem. 2001 Jun 4;40(12):2751-5.

PMID:
11375691
27.

Management of the resistant myelodysplastic or arthrogrypotic clubfoot with the Verebelyi-Ogston procedure.

Spires TD, Gross RH, Low W, Barringer W.

J Pediatr Orthop. 1984 Nov;4(6):705-10.

PMID:
6511898

Supplemental Content

Loading ...
Support Center